Luis E. Raez

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Harmonizing definitions in liquid biopsy: A terminology framework by the international society of liquid biopsy

  The Journal of Liquid Biopsy · 2026-03-25 · 1 citations

• Ready, Set, Screen: Evaluating Community Readiness for Lung Cancer Screening Among Non-Hispanic Black Populations in Florida: Brief Report

  JTO Clinical and Research Reports · 2026-02-11

• OP72 Clinical And Economic Impact Of The Availability Of Innovative Therapies For Advanced Lung Cancer In Latin America

  International Journal of Technology Assessment in Health Care · 2025-12-01

• Corrigendum to “Clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in Latin America: a population-based secondary data study”- the Lancet Regional Health—Americas 2025; Volume 49: 101172; DOI: 10.1016/j.lana.2025.101172

  The Lancet Regional Health - Americas · 2025-11-19

• Liquid Biopsy Innovation: ctDNA Accurately Detects Systemic Recurrence in Lung Cancer with Strong Concordance to Imaging

  The Journal of Liquid Biopsy · 2025-11-01

• Correction: Purohit et al. Incidental Pulmonary Nodule (IPN) Programs Working Together with Lung Cancer Screening and Artificial Intelligence to Increase Lung Cancer Detection. Cancers 2025, 17, 1143

  Cancers · 2025-10-17

• The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast

  Oncology and Therapy · 2025-10-11 · 1 citations

• Supplemental Fig S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint

  2025-09-17

• Supplemental Table S2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint

  2025-09-17

• Supplemental Fig S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint

  2025-09-17

• Supplemental Table S1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint

  2025-09-17

• Supplemental Table S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint

  2025-09-17

• Table 1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint

  2025-09-17

• Data from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint

  2025-09-17

• Supplemental Table S3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint

  2025-09-17

• Table 2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint

  2025-09-17

• Table 3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint

  2025-09-17

• Supplemental Fig S10 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint

  2025-09-17

• Supplemental Table S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint

  2025-09-17

• Supplemental Fig S4 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint

  2025-09-17